NeuroSense Therapeutics, Ltd. (NRSN): Market Cap to Revenue Ratio
Monitoring the P/S ratio of NeuroSense Therapeutics (NRSN) demonstrates that share prices depend on the success of clinical trials within a patent-protected sector, where the current level is . The financial potential relies on a future monopoly in ALS therapy and the pricing power to independently determine drug costs. The high efficiency of the R&D pipeline and the breakthrough in developing the combined drug PrimeC confirm the fundamental stability of the business.
NeuroSense Therapeutics (NRSN) - metric breakdowns and financial figures
- current quotes and average value forecast:
- stock exchange capitalization data:
- business book valuation details:
- issuer credit burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio NeuroSense Therapeutics|NRSN - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio neurosense-tx.com|NRSN - Company Aggregate Debts|Debt to Net Assets Ratio NeuroSense Therapeutics, Ltd.|NRSN - Company Long-Term Debts|Short-Term Debt NeuroSense Therapeutics|Intermediate Coverage Ratio neurosense-tx.com
- net income and valuation ratios data:
NRSN - Net Profit|Projected Future Earnings NeuroSense Therapeutics|NRSN - Price to Earnings Ratio|Price to Expected Earnings Ratio neurosense-tx.com|NRSN - PEG Multiple|Company Value to EBITDA NeuroSense Therapeutics, Ltd.|NRSN - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) NeuroSense Therapeutics|NRSN - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months neurosense-tx.com|NRSN - Earnings growth in current year|Consensus forecast of earnings per share growth for next year NeuroSense Therapeutics
- issuer revenue and sales details:
General company analysis:NeuroSense Therapeutics Ltd, NRSN
Investors are assessing the stability of NeuroSense Therapeutics (NRSN) through the lens of its assets' market value. The P/S ratio correlates total market capitalization with annual sales volume, determining the premium the market is willing to pay per unit of revenue. Analyzing the revenue multiple level allows for the identification of pricing anomalies and overvaluation risks. For a biotech firm with monopoly potential in ALS therapy, this indicator reflects future expectations regarding exclusive pricing power.
Competing companies
BIIB - Price to Sales|Price-to-Revenue Ratio Neurocrine Biosciences, Inc. NBIX|RGC: Market Cap to Revenue Ratio|AXSM - Price-to-Revenue Ratio|Price-to-Revenue Coefficient ACADIA Corp ACAD|XENE: P/S Multiple|Price to Sales vikingtherapeutics.com (VKTX)|Market Cap to Revenue SUPN|CPRX: Market Capitalization-to-Revenue Ratio|Market Cap to Revenue DNLI (Denali Therapeutics Inc)|Market Cap to Sales Volume HRMY|P/S Multiple BHVN (Biohaven Ltd.)|Market Capitalization-to-Revenue Ratio AMLX|Trevi Therapeutics, Inc. - P/S Multiple|Price to Sales Praxis Precision Medicines Inc|Anavex Corp (AVXL) - Price-to-Revenue Ratio|CeriBell EEG - Market Capitalization-to-Revenue Ratio|PRTA (Prothena Biosciences) - P/S Multiple|P/S Multiple Alector Therapeutics|Price-to-Revenue Ratio Annexon (ANNX)|OMER: Price-to-Sales Ratio|P/S Multiple NGNE (Neurogene Corp)|AC Immune Inc (ACIU) - Price to Sales|VYGR: Market Cap to Revenue|NMRA - P/S Multiple|SCLX (Scilex) - Market Cap to Revenue|TVGN: Market Cap to Sales Volume|ACOG (Alpha Cognition Inc) - P/S Multiple|Cognition Therapeutics Inc. (CGTX) - Price-to-Revenue Coefficient|P/S Multiple IKT|Market Cap to Revenue cassavasciences.com SAVA|Price-to-Revenue Ratio Assertio ASRT|Price-to-Revenue Coefficient Coya Therapeutics Inc (COYA)|VTGN - Price-to-Revenue Ratio|OVID (Ovid Therapeutics Inc.) - Market Cap to Revenue Ratio|Acumen Pharmaceuticals (ABOS) - Price-to-Revenue Ratio|cervomed.com - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Alterity Therapeutics Ltd.|Clene Nanomedicine (CLNN) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio PepGen Inc. (PEPG)|Jupiter Neurosciences, Inc. - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Relmada Therapeutics RLMD|ANVS: Market Cap to Revenue Ratio|Grace Tx - P/S Multiple|Price to Sales Firefly Neuroscience, Inc.|KLTO (anewmeds.com) - Market Cap to Revenue|Reviva Pharmaceuticals, Inc. (RVPH) - P/S Multiple|Price-to-Revenue Ratio MetaVia Inc.|NRXS: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Helius Medical (HSDT)|PASG - Price to Sales|Price-to-Revenue Ratio Neuphoria Therapeutics NEUP|NERV: Market Cap to Revenue Ratio|Athira Pharma, Inc. - P/S Multiple|Price to Sales addextherapeutics.com|ALZN (alzamend.com) - Market Cap to Revenue|Cyclerion Therapeutics, Inc. (CYCN) - P/S Multiple|Price-to-Revenue Ratio Protagenic Therapeutics Inc.|KTTA: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Cortigent, Inc. (CRGT)|ATXI - Price to Sales|Price-to-Revenue Ratio BrainStorm Cell Therapeutics BCLI|Price-to-Revenue Coefficient Cara Therapeutics Inc. (CARA)|Chromocell Therapeutics Corporation - P/S Multiple|Price to Sales Eliem Therapeutics|intracellulartherapies.com (ITCI) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio LBPH|Price-to-Revenue Ratio Marinus Pharmaceuticals, Inc.|NKGen Biotech Inc (NKGN) - Price-to-Revenue Coefficient|P/S Multiple NRBO|SAGE - Price to Sales|Synaptogenix, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio TRVN|VIGL: Market Cap to Revenue|anewmeds.com - Market Cap to Sales Volume|CERE: P/S Multiple
